This week in MedTech, major acquisitions and targeted investments are reshaping the competitive landscape. Abbott’s $21B move for Exact Sciences, GE HealthCare’s push into AI-driven imaging with Intelerad’s acquisition, and Solventum’s expansion into soft tissue repair mark strategic shifts with a long-term view from industry leaders. Fresh funding for robotics, vascular interventions, and novel diagnostics – from Distalmotion to Okami and VahatiCor – highlights continued momentum across emerging technologies. More details below.

Abbott plans to acquire Exact Sciences for $21B

Confirmation of the deal comes just one day after reports initially suggested that Abbott and Exact Sciences were in negotiations. Shares of EXAS skyrocketed by more than 20% in response to the report.

The deal will allow Abbott to enter and lead in the growing cancer diagnostics segment. Under the agreement, Exact Sciences shareholders receive $105 per common share. It represents a total equity value of approximately $21 billion.

CEO Robert Ford

Last week’s tracker: Cornerstone Robotics, Beacon Biosignals & more

GE HealthCare to advance enterprise imaging through Intelerad acquisition

GE HealthCare announced it agreed to acquire Intelerad, a medical imaging software provider, for $2.3 billion. The company plans to complete the deal in cash as it looks to add cloud-enabled and AI-powered imaging solutions.

It says the deal furthers its aim to triple its offerings of cloud-enabled products by 2028. The company expects to complete the acquisition in the first half of 2026.

President and CEO Roland Rott

Solventum to acquire soft tissue repair company Acera Surgical

Solventum announced its first tuck-in acquisition as a stand-alone company; it will acquire Acera Surgical in a deal worth up to $900 million.

The deal features a $725 million cash payment, plus up to $125 million in contingent cash payments based on future milestones.

CEO Bryan Hanson

Sofinnova Partners closes $750M Fund for Life Sciences investments

The fund will invest in early-stage biopharmaceutical and medical technology companies across Europe and North America. The fund attracted support from institutional investors including sovereign wealth funds, pharmaceutical companies, corporates, insurance companies, foundations, and family offices.

Commitments came from Europe, North America, Asia, and the Middle East, with a majority of returning limited partners and new investors.

Chairman and Managing Partner Antoine Papiernik

Distalmotion raises $150M to support Dexter surgical robot as it targets ASCs

The company closed a Series G financing round worth $150 million to support its Dexter surgical robot. Revival Healthcare Capital led the financing, which also included inside investor participation.

It plans to use the funding to accelerate the U.S. commercial adoption of Dexter, its soft tissue surgical robot system. Other uses could include further product development initiatives.

CEO Greg Roche

Okami secures $45m to advance clinical programmes for vascular disease

Okami Medical has closed a financing round, raising $45m, to expand its commercial presence and progress clinical programmes focused on improving outcomes for vascular disease patients.

New investor Gilde Healthcare spearheaded the oversubscribed round, with participation from current investors US Venture Partners and Vensana Capital. This capital will also be used to develop Okami’s devices for peripheral vessel occlusion.

CEO Drew Hykes

VahatiCor wins $23m for Coronary Microvascular Dysfunction device

The company announced the successful closing of its $23 million Series B financing led by S3 Ventures, with support from Intuitive Ventures, and a strategic investor.

The capital will be deployed toward advancing SERRA-I enrollment, engineering development, and preparation for subsequent studies, including planning for pivotal trials and regulatory interactions.

Co-Founder Marwan Berrada-Sounni

1nhaler raises $2M for cardboard inhaler device

With the latest fundraising, the company adds to $2.5 million brought in nearly two years ago. Archangels led the round, while Scottish Enterprise and BBB Investments supported it.

The investment enables 1nhaler to advance its platform toward a first marketing authorization application in Europe. It targets late 2027 for that milestone.

Co-Founder and CEO Lisa McMyn